Endocrine Abstracts

Background: Metastatic neuroendocrine neoplasms (NENs) constitute a heterogeneous group of uncurable cancers with limited treatment options. Lenvatinib is an oral multiple kinase inhibitor that showed activity in gastroenteropancreatic neuroendocrine tumors in the phase II Talent Trial at a starting dose of 24 mg per day. Although a confirmatory phase III study was never conducted, the drug is available for use off-label.Methods: We retrospectively revie...

Differentiated thyroid carcinoma (DTC) is viewed as an indolent disease but 5–15% of patients (pts) become refractory to RAI treatment. This is associated with poor prognosis, a 3–6 years life expectancy and accounts for approximately 200 deaths per year in Canada. There is no universal definition of rDCT and management evolves over time, with either monitoring or systemic therapy including LEN. In the Select Study on LEN in DTC, LEN provided a 19.4 month (mo) medi...